Gain Therapeutics logo
Gain Therapeutics
GANX | NASDAQ
Chart Builder DCF Calculator
$0.94
-$0.10 (-9.62%)
At close: Nov 16, 2026, 4:00 PM ET
$1.10
+$0.16 (+17.02%)
After-hours: Nov 16, 2026, 6:40 PM ET

Gain Therapeutics Company Profile

Company profile explained

Company Profile

Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.

Key Executives

Name Position
Gene Mack President, CEO, Director & Interim CFO
Terenzio Ignoni Chief Operating Officer
Gianluca Fuggetta Senior Vice President of Finance & Principal Financial Officer
Joanne Taylor Chief Scientific Officer
Khalid Islam Chairman & Founder

Latest SEC Filings

Date Type Title
Oct 30, 2026 4 Filing
Oct 30, 2026 3 Filing
Oct 28, 2026 8-K Current Report
Oct 01, 2026 8-K Current Report
Sep 28, 2026 8-K Current Report
Aug 11, 2026 10-Q Quarterly Report
Aug 11, 2026 8-K Current Report
Jul 17, 2026 4 Filing
Jul 17, 2026 4 Filing
Jul 17, 2026 4 Filing
View All SEC Filings ➞
Gain Therapeutics
Gain Therapeutics logo
Country United States
IPO Date Mar 19, 2021
Industry Biotechnology
Sector Healthcare
Employees 21
CEO Gene Mack

Contact Details

4800 Montgomery Lane Bethesda, Maryland 20814 United States

Stock Details

Ticker Symbol GANX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001819411
CUSIP Number 36269B105
ISIN Number US36269B1052
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.